Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Akebia Therapeutics (NASDAQ: AKBA) said its CEO John P. Butler and CFO/Chief Business Officer Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 8:00 AM ET in Miami.
A webcast will be available via the company’s Investors website following the conference. The conference runs March 8-11, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
On the day this news was published, AKBA declined 3.17%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AKBA was down 3.82% with peers ESPR and EVO in the momentum scan both moving down about 7–8%, while sector peers showed mixed single‑stock moves. This points to broader downward pressure alongside stock‑specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Quarterly earnings | Positive | +9.1% | Stronger 2025 revenues and cash with guidance for Vafseo growth. |
| Feb 19 | Earnings date set | Neutral | +0.0% | Announcement of timing and access details for earnings call. |
| Feb 04 | Conference appearance | Neutral | -2.8% | Management participation in Guggenheim biotech summit fireside chat. |
| Feb 02 | Inducement grants | Neutral | +2.2% | Stock option inducement awards to new employees under Nasdaq rules. |
| Jan 12 | Pipeline update | Positive | -7.9% | Vafseo access growth and multiple mid‑ to late‑stage trial milestones. |
Earnings and fundamental updates have sometimes driven sizable moves, with at least one notably negative reaction despite detailed pipeline and commercial progress.
Over the last few months, Akebia has highlighted Vafseo commercial ramp, rare kidney disease pipeline progress, and detailed 2025 financials. An earnings report on Feb 26, 2026 saw a 9.09% gain, while broader 2026 pipeline updates on Jan 12, 2026 coincided with a -7.89% move. Prior conference participation and inducement grants produced modest price changes. Today’s conference appearance fits the pattern of ongoing investor outreach rather than a new fundamental inflection point.
Market Pulse Summary
This announcement centers on Akebia management’s participation in the Leerink Partners conference on March 9, 2026, continuing a cadence of investor-facing events. Recent history featured strong 2025 revenue growth, higher cash balances, and progress across Vafseo and rare kidney disease programs, balanced against ongoing losses and Auryxia generic risk. Investors may watch for any updated commentary on commercial trends, trial timelines, financing needs, and how management frames the competitive kidney-disease landscape.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9 at 8:00 AM ET.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
The Leerink Partners 2026 Global Healthcare Conference will take place March 8-11, 2026, in Miami.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When will Akebia Therapeutics (AKBA) present at the Leerink Partners 2026 Global Healthcare Conference?
Who from Akebia (AKBA) will participate in the company’s Leerink 2026 Fireside Chat?
How can investors watch Akebia Therapeutics’ (AKBA) Leerink 2026 presentation?
What is the schedule for the Leerink Partners 2026 Global Healthcare Conference where Akebia (AKBA) will appear?
Will Akebia Therapeutics (AKBA) share financial results during the Leerink 2026 Fireside Chat?
Where is the Leerink Partners 2026 Global Healthcare Conference being held for Akebia’s (AKBA) presentation?
